Common Stock, $.001 par value
- Symbol
- COSM
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 3.03, 5.02, 5.03, 5.07, 9.01 · 8-K
Cosmos Health Inc.
COSMNASDAQEQUITYCurrent
Material Modification to Rights of Security Holders · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
ITEM 3.03. MATERIAL MODIFICATIONS TO RIGHTS OF SECURITY HOLDERS. The disclosure required by this Item 3.03 is included in Item 5.03 of this Current Report on Form 8-K and is incorporated herein by reference.
Company context
Cosmos Health Inc. (NASDAQ: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is avai
Current securities
Registered securities in this filing
COSMOS HEALTH INC. · 8-K · Filed 2026-07-16
Disclosure sections
Item 3.03Item 3.03 - Material Modification to Rights
ITEM 3.03. MATERIAL MODIFICATIONS TO RIGHTS OF SECURITY HOLDERS.
The disclosure required by this Item 3.03 is included in Item 5.03 of this Current Report on Form 8-K and is incorporated herein by reference.
Item 5.02Item 5.02 - Departure/Election of Directors
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
As described under Item 5.07 of this Current Report on Form 8-K, at the Company’s 2026 Annual Meeting of Stockholders held on July 15, 2026 (the “Annual Meeting”), the stockholders of the Company elected the following to serve as directors of the Company until the next Annual Meeting and until their successors are duly elected and qualified:
Grigorios Siokas
Demetrios G. Demetriades
John J. Hoidas
Dr. Anastasios Aslidis
Suhel Bhutawala
Theodoros C. Karkantzos
Item 5.03Item 5.03 - Amendments to Articles/Bylaws
ITEM 5.03. AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.
As described under Item 5.07 of this Current Report on Form 8-K, at the Company’s 2026 Annual Meeting, the stockholders of the Company approved the proposed issuance and designation of one hundred thousand (100,000) shares of Series B Preferred Stock of the Company. The material terms of Series B Preferred Stock are described in detail under “Proposal 4: Approval of Designation and Issuance of Series B Preferred Stock,” commencing on page 32 of the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on June 2, 2026, in connection with the Annual Meeting. The Company will file a certificate of designation with the Secretary of State of Nevada, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the shares of Series B Preferred Stock, the form of which is attached hereto as Exhibit A.
Item 5.07Item 5.07 - Submission of Matters to Vote
ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
On July 15, 2026, the Company held its 2026 Annual Meeting. Of the 60,043,491 shares of common stock of the Company outstanding on the record date, 28,315,417 shares were present at the Annual Meeting in person or by proxy, representing approximately 47% of the total outstanding shares eligible to vote. All proposals passed, and the directors recommended by the Company were elected.
The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting are as follows:
Proposal 1 - Election of Directors
Name Votes For Votes Withheld Percentage Affirmative
────────────────────────────────────────────────────────────────────────────────────────────
Grigorios Siokas 22,388,863 5,926,554 79.07%
Demetrios G. Demetriades 23,362,049 4,953,368 82.51%
John J. Hoidas 22,945,782 5,369,635 81.04%
Dr. Anastasios Aslidis 23,622,205 4,693,212 83.43%
Suhel Bhutawala 22,946,202 5,369,215 81.04%
Theodoros C. Karkantzos 23,847,672 4,467,745 84.22%
Proposal 2 - The Ratification of the Appointment of the Company’s Independent Registered Public Accounting Firm
Votes For: 23,852,605
Votes Against: 4,391,554
Abstain: 71,258
Percentage Affirmative: 84.24%
Proposal 3 - Approval of Company’s 2026 Equity Omnibus Plan
Votes For: 22,534,586
Votes Against: 5,673,149
Abstain: 107,682
Percentage Affirmative: 79.58%
Proposal 4 - Approval of Designation and Issuance of the Company’s Series B Preferred Stock
Votes For: 22,363,076
Votes Against: 5,818,559
Abstain: 133,782
Percentage Affirmative: 78.98%